目的 研究復(fù)方芩蘭口服液與銀黃口服液治療新型冠狀病毒感染的臨床療效。方法 選取2022年11月—2023年1月天津市第三中心醫(yī)院收治的輕中度新型冠狀病毒感染患者280例為研究對象，根據(jù)用藥差別將患者分為銀黃組（145例）和復(fù)方芩蘭組（135例）。兩組患者在38.5 ℃以下單用復(fù)方芩蘭口服液或銀黃口服液進行清熱治療。復(fù)方芩蘭組患者口服復(fù)方芩蘭口服液，10～20 mL/次，3次/d；銀黃組口服銀黃口服液組，10～20 mL/次，3次/d。兩組均治療7 d。觀察兩組的臨床療效，比較兩組咽痛、聲音嘶啞、咽部干、發(fā)熱的緩解情況，同時比較兩組治療前后白細(xì)胞介素-6（IL-6）和腫瘤壞死因子-α（TNF-α）的變化情況。結(jié)果 治療后，復(fù)方芩蘭組總有效率是98.52%，顯著高于銀黃組的90.34%（P＜0.05）。治療后，復(fù)方芩蘭組咽痛和發(fā)熱的總有效率分別是98.51%、97.78%，顯著高于銀黃組的89.66%、88.97%（P＜0.05），兩組聲音嘶啞和咽部干燥的總有效率差異無統(tǒng)計學(xué)意義。治療后，兩組患者血清IL-6、TNF-α水平均較治療前顯著降低（P＜0.05），且治療后，復(fù)方芩蘭組TNF-α、IL-6水平低于銀黃組（P＜0.05）。結(jié)論 復(fù)方芩蘭口服液治療輕型和中型新型冠狀病毒感染患者具有較好的臨床療效，可明顯改善患者咽痛和發(fā)熱癥狀，降低TNF-α和IL-6水平。

Objective To study the clinical effect of Compound Qinlan Oral Liquid and Yinhuang Oral Liquid in treatment of novel coronavirus infection. Methods A total of 280 patients with mild to moderate novel coronavirus infection admitted to the Third Central Hospital of Tianjin from November 2022 to January 2023 were selected as the study objects. According to the differences in drug use, the patients were divided into Yinhuang group (145 cases) and Compound Qinlan group (135 cases). Two groups of patients were treated with Compound Qinlan Oral Liquid or Yinhuang Oral Liquid to clear heat under 38.5 ℃. Patients in the Compound Qinlan group were po administered with Compound Qinlan Oral Liquid, 10 — 20 mL/time, 3 times daily. Patients in the Yinhuang group were po administered with Yinhuang Oral Liquid, 10 — 20 mL/time, 3 times daily. Both groups were treated for 7 d. The clinical efficacy of two groups was observed, and the relief of pharyngeal pain, hoarseness, dryness of pharynx and fever between the two groups were compared. The changes of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) before and after treatment were also compared between the two groups. Results After treatment, the total effective rate of Compound Qinlan group was 98.52%, which was significantly higher than that of Yinhuang group (90.34%) (P < 0.05). After treatment, the total effective rates of pharyngeal pain and fever in Compound Qinlan group were 98.51% and 97.78%, respectively, which were significantly higher than 89.66% and 88.97% in Yinhuang group (P < 0.05). There was no statistical significance in the total effective rates of hoarseness and dryness of pharynx between the two groups. After treatment, serum levels of IL-6 and TNF-α in two groups were significantly decreased compared with before treatment (P < 0.05), and after treatment, the levels of TNF-α and TNF-6 in Compound Qinlan group were lower than those in Yinhuang group (P < 0.05). Conclusion Compound Qinlan Oral Liquid has good clinical efficacy in treatment of mild and medium novel coronavirus infection patients, and can significantly improve the symptoms of pharyngeal pain and fever, and reduce the levels of TNF-α and IL-6.

R974